MabSpace launches Phase 1 Trial of 2nd Generation PD-L1 antibody
Recently, MabSpace Biosciences announced that the first subject had been dosed in a Phase 1 clinical study of MSB2311 in Texas, USA, for the treatment of advanced solid tumors. Developed using proprietary immune tolerance breaking technology, MSB2311 is a 2nd Generation PD-L1 antibody with a unique pH-dependent antigen binding element that enables intra-tumor recycling and enhances tumor penetration.
Wan Yuntao, vice president and head of clinical development operations at MabSpace, said, “With seamless execution we moved quickly from IND clearance by FDA to first patient being dosed in less than 2 months, by Dr. Papadopoulos and his team at the START clinic of San Antonio, Texas. We’d also like to thank Dr. Adjei from Mayo Clinic, for his expertise input into the trial design from the very beginning. Soon, he will lead two prominent Mayo investigators to join the study. Of course, we couldn’t have achieved such a speedy and quality start without the strong support from our CRO partners Syneos Healthcare and Q2 Solutions.”
This study, MSB2311-CSP-001, is the first-in-human, open-label, Phase 1 dose-escalation study of MSB2311, a humanized anti-PD-L1 monoclonal antibody in patients with advanced solid tumors. A separate China Phase 1 study with several disease expansion cohorts to evaluate preliminary efficacy is at the final regulatory review stage, and is expected to be launched soon upon CFDA approval.
Founder and CEO of MabSpace Biosciences.
“We are excited to start the testing of MSB2311 in cancer patients and can’t wait to see how well the superior pre-clinical efficacy of MSB2311 will translate in clinical setting to benefit more patients” Qian, Xueming, founder and CEO, MabSpace Biosciences, said.
About MabSpace Biosciences
MabSpace Biosciences Co. Ltd, is a global biotechnology company specializing in discovering and development of innovative antibody therapeutics. Headquartered in Suzhou, MabSpace has a fully-integrated antibody discovery and development facility in Biobay, SIP. Based on its proprietary immune tolerance breaking technology, MabSpace has built up more than 10 pipelines in immune-oncology. For more information, visit www.mabspacebio.com